Heron Therapeutics Inc (HRTX) - Financial and Strategic SWOT Analysis Review
Heron Therapeutics Inc (HRTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Heron Therapeutics Inc (Heron) is a biotechnology company that uses proprietary polymer-based drug delivery platform to develop novel, patient-focused drugs for patients suffering from cancer and pain. Its proprietary Biochronomer technology is a polymer-based drug delivery platform, which improves the therapeutic profile of injectable pharmaceuticals. The company's marketed products include, Sustol is an extended-release injection indicated in combination with other antiemetics in adults for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens; Cinvanti for chemotherapy-induced nausea and vomiting (CINV) prevention and Zynrelef (HTX-011) for treatment of somatic postoperative pain from smallto medium-sized surgical wounds in adults. Heron's developmental pipeline includes HTX-019 for postoperative nausea and vomiting; and HTX-034 for postoperative pain. Heron is headquartered in San Diego, California, the US.
Heron Therapeutics Inc Key Recent Developments
Feb 24,2021: Heron Therapeutics announces financial results for the three and twelve months ended December 31, 2020 and highlights recent corporate updates
Jan 11,2021: Heron Therapeutics highlights progress in pain management and CINV franchises and announces new development program
Nov 05,2020: Heron Therapeutics announces financial results for the three and nine months ended September 30, 2020 and highlights recent corporate updates
Oct 13,2020: Heron Therapeutics announces election of directors
Aug 05,2020: Heron Therapeutics announces financial results for the three and six months ended June 30, 2020 and highlights recent corporate updates
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Heron Therapeutics Inc (Heron) is a biotechnology company that uses proprietary polymer-based drug delivery platform to develop novel, patient-focused drugs for patients suffering from cancer and pain. Its proprietary Biochronomer technology is a polymer-based drug delivery platform, which improves the therapeutic profile of injectable pharmaceuticals. The company's marketed products include, Sustol is an extended-release injection indicated in combination with other antiemetics in adults for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens; Cinvanti for chemotherapy-induced nausea and vomiting (CINV) prevention and Zynrelef (HTX-011) for treatment of somatic postoperative pain from small
Heron Therapeutics Inc Key Recent Developments
Feb 24,2021: Heron Therapeutics announces financial results for the three and twelve months ended December 31, 2020 and highlights recent corporate updates
Jan 11,2021: Heron Therapeutics highlights progress in pain management and CINV franchises and announces new development program
Nov 05,2020: Heron Therapeutics announces financial results for the three and nine months ended September 30, 2020 and highlights recent corporate updates
Oct 13,2020: Heron Therapeutics announces election of directors
Aug 05,2020: Heron Therapeutics announces financial results for the three and six months ended June 30, 2020 and highlights recent corporate updates
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
SECTION 1 - ABOUT THE COMPANY
Heron Therapeutics Inc - Key Facts
Heron Therapeutics Inc - Key Employees
Heron Therapeutics Inc - Key Employee Biographies
Heron Therapeutics Inc - Major Products and Services
Heron Therapeutics Inc - History
Heron Therapeutics Inc - Company Statement
Heron Therapeutics Inc - Locations And Subsidiaries
Head Office
SECTION 2 – COMPANY ANALYSIS
Company Overview
Heron Therapeutics Inc - Business Description
Product Category: Cinvanti
Overview
Performance
Product Category: Sustol
Overview
Performance
R&D Overview
Heron Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Heron Therapeutics Inc - Strengths
Heron Therapeutics Inc - Weaknesses
Heron Therapeutics Inc - Opportunities
Heron Therapeutics Inc - Threats
Heron Therapeutics Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Heron Therapeutics Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Feb 24, 2021: Heron Therapeutics announces financial results for the three and twelve months ended December 31, 2020 and highlights recent corporate updates
Jan 11, 2021: Heron Therapeutics highlights progress in pain management and CINV franchises and announces new development program
Nov 05, 2020: Heron Therapeutics announces financial results for the three and nine months ended September 30, 2020 and highlights recent corporate updates
Oct 13, 2020: Heron Therapeutics announces election of directors
Aug 05, 2020: Heron Therapeutics announces financial results for the three and six months ended June 30, 2020 and highlights recent corporate updates
Aug 05, 2020: Heron Therapeutics: Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers
Mar 02, 2020: Heron Therapeutics announces financial results for the three and twelve months ended december 31, 2019 and highlights recent corporate updates
Jan 13, 2020: Heron Therapeutics highlights progress in pain management and CINV franchises
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Heron Therapeutics Inc - Key Facts
Heron Therapeutics Inc - Key Employees
Heron Therapeutics Inc - Key Employee Biographies
Heron Therapeutics Inc - Major Products and Services
Heron Therapeutics Inc - History
Heron Therapeutics Inc - Company Statement
Heron Therapeutics Inc - Locations And Subsidiaries
Head Office
SECTION 2 – COMPANY ANALYSIS
Company Overview
Heron Therapeutics Inc - Business Description
Product Category: Cinvanti
Overview
Performance
Product Category: Sustol
Overview
Performance
R&D Overview
Heron Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Heron Therapeutics Inc - Strengths
Heron Therapeutics Inc - Weaknesses
Heron Therapeutics Inc - Opportunities
Heron Therapeutics Inc - Threats
Heron Therapeutics Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Heron Therapeutics Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Feb 24, 2021: Heron Therapeutics announces financial results for the three and twelve months ended December 31, 2020 and highlights recent corporate updates
Jan 11, 2021: Heron Therapeutics highlights progress in pain management and CINV franchises and announces new development program
Nov 05, 2020: Heron Therapeutics announces financial results for the three and nine months ended September 30, 2020 and highlights recent corporate updates
Oct 13, 2020: Heron Therapeutics announces election of directors
Aug 05, 2020: Heron Therapeutics announces financial results for the three and six months ended June 30, 2020 and highlights recent corporate updates
Aug 05, 2020: Heron Therapeutics: Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers
Mar 02, 2020: Heron Therapeutics announces financial results for the three and twelve months ended december 31, 2019 and highlights recent corporate updates
Jan 13, 2020: Heron Therapeutics highlights progress in pain management and CINV franchises
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
Heron Therapeutics Inc, Key Facts
Heron Therapeutics Inc, Key Employees
Heron Therapeutics Inc, Key Employee Biographies
Heron Therapeutics Inc, Major Products and Services
Heron Therapeutics Inc, History
Heron Therapeutics Inc, Key Competitors
Heron Therapeutics Inc, Ratios based on current share price
Heron Therapeutics Inc, Annual Ratios
Heron Therapeutics Inc, Annual Ratios (Cont...1)
Heron Therapeutics Inc, Interim Ratios
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Heron Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Heron Therapeutics Inc, Key Facts
Heron Therapeutics Inc, Key Employees
Heron Therapeutics Inc, Key Employee Biographies
Heron Therapeutics Inc, Major Products and Services
Heron Therapeutics Inc, History
Heron Therapeutics Inc, Key Competitors
Heron Therapeutics Inc, Ratios based on current share price
Heron Therapeutics Inc, Annual Ratios
Heron Therapeutics Inc, Annual Ratios (Cont...1)
Heron Therapeutics Inc, Interim Ratios
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Heron Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
Heron Therapeutics Inc, Performance Chart (2016 - 2020)
Heron Therapeutics Inc, Ratio Charts
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021
Heron Therapeutics Inc, Performance Chart (2016 - 2020)
Heron Therapeutics Inc, Ratio Charts
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021